Osteochondral angiogenesis and increased protease inhibitor expression in OA

Osteoarthritis and Cartilage

Volumn 18, Issue 4, 2010, Pages 563-571

  Franses R E ^a   McWilliams, D F ^a   Mapp, P I ^a   Walsh, D A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Angiogenesis; Cartilage; Osteoarthritis; Protease; TIMP

Indexed keywords

CORTICOSTEROID; GLUCOSAMINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN;

AGED; ANGIOGENESIS; ARTICLE; AUTOPSY; CARTILAGE CELL; CELLULAR DISTRIBUTION; CHONDROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNEE OSTEOARTHRITIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; TIBIA; UPREGULATION;

CHONDROCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOARTHRITIS, KNEE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE INHIBITORS; TIBIA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950021683     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.11.015     Document Type: Article

References (33)

1. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52:237-268.
2. Walsh D.A., Haywood L. Angiogenesis: a therapeutic target in arthritis. Curr Opin Investig Drugs 2001, 2:1054-1063.
3. Suri S., Gill S.E., Massena de Camin S., Wilson D., McWilliams D.F., Walsh D.A. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis 2007, 66:1423-1428.
4. Walsh D.A., Bonnet C.S., Turner E.L., Wilson D., Situ M., McWilliams D.F. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007, 15:743-751.
5. Walsh D.A. Angiogenesis and arthritis. Rheumatology (Oxford) 1999, 38:103-112.
6. Lane L.B., Bullough P.G. Age-related changes in the thickness of the calcified zone and the number of tidemarks in adult human articular cartilage. J Bone Joint Surg Br 1980, 62:372-375.
7. Lane L.B., Villacin A., Bullough P.G. The vascularity and remodelling of subchondrial bone and calcified cartilage in adult human femoral and humeral heads. An age- and stress-related phenomenon. J Bone Joint Surg Br 1977, 59:272-278.
8. Pufe T., Petersen W., Tillmann B., Mentlein R. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum 2001, 44:1082-1088.
9. Hashimoto S., Creighton-Achermann L., Takahashi K., Amiel D., Coutts R.D., Lotz M. Development and regulation of osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage 2002, 10:180-187.
10. Eisenstein R., Sorgente N., Soble L.W., Miller A., Kuettner K.E. The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 1973, 73:765-774.
11. Shibakawa A., Yudoh K., Masuko-Hongo K., Kato T., Nishioka K., Nakamura H. The role of subchondral bone resorption pits in osteoarthritis: MMP production by cells derived from bone marrow. Osteoarthritis Cartilage 2005, 13:679-687.
12. Moses M.A., Sudhalter J., Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990, 248:1408-1410.
13. Sugino T., Yamaguchi T., Ogura G., Kusakabe T., Goodison S., Homma Y., et al. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol 2007, 212:152-160.
14. Davidson R.K., Waters J.G., Kevorkian L., Darrah C., Cooper A., Donell S.T., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 2006, 8:R124.
15. Jacoby A.S., Melrose J., Robinson B.G., Hyland V.J., Ghosh P. Secretory leucocyte proteinase inhibitor is produced by human articular cartilage chondrocytes and intervertebral disc fibrochondrocytes. Eur J Biochem 1993, 218:951-957.
16. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.
17. Treadwell B.V., Pavia M., Towle C.A., Cooley V.J., Mankin H.J. Cartilage synthesizes the serine protease inhibitor PAI-1: support for the involvement of serine proteases in cartilage remodeling. J Orthop Res 1991, 9:309-316.
18. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001, 276:12501-12504.
19. Milner J.M., Elliott S.F., Cawston T.E. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001, 44:2084-2096.
20. Williams S.E., Brown T.I., Roghanian A., Sallenave J.M. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006, 110:21-35.
21. Brown R.A., Weiss J.B. Neovascularisation and its role in the osteoarthritic process. Ann Rheum Dis 1988, 47:881-885.
22. Stephens R.W., Ghosh P., Taylor T.K. The pathogenesis of osteoarthrosis. Med Hypotheses 1979, 5:809-816.
23. Joronen K., Kahari V.M., Vuorio E. Temporospatial expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in mouse antigen-induced arthritis. Histochem Cell Biol 2005, 124:535-545.
24. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049.
25. Walsh D.A., Wilson D. Post-mortem collection of human joint tissues for research. Rheumatology (Oxford) 2003, 42:1556-1558.
26. Haywood L., McWilliams D.F., Pearson C.I., Gill S.E., Ganesan A., Wilson D., et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003, 48:2173-2177.
27. Mankin H.J., Dorfman H., Lippiello L., Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971, 53:523-537.
28. Nagaosa Y., Mateus M., Hassan B., Lanyon P., Doherty M. Development of a logically devised line drawing atlas for grading of knee osteoarthritis. Ann Rheum Dis 2000, 59:587-595.
29. Walter H., Kawashima A., Nebelung W., Neumann W., Roessner A. Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation. Pathol Res Pract 1998, 194:73-81.
30. Hulejova H., Baresova V., Klezl Z., Polanska M., Adam M., Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007, 38:151-156.
31. Lisignoli G., Toneguzzi S., Pozzi C., Piacentini A., Grassi F., Ferruzzi A., et al. Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin Exp Immunol 1999, 116:371-378.
32. Pufe T., Harde V., Petersen W., Goldring M.B., Tillmann B., Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol 2004, 202:367-374.
33. Walsh D.A., Yousef A., McWilliams D.F., Hill R., Hargin E., Wilson D., et al. Evaluation of a Photographic Chondropathy Score (PCS) for pathological samples in a study of inflammation in tibiofemoral osteoarthritis. Osteoarthritis Cartilage 2009, 17:304-312.